Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?

Dong Yun Kim^{1

2}, Jun Yong Park^{2

3

4}

Affiliations

¹ Department of Pharmacology, Yonsei University Graduate School of Medicine, Seoul, South Korea.
² Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
³ Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea.
⁴ Yonsei Liver Center, Severance Hospital, Seoul, South Korea.

Editorial

Dong Yun Kim et al. Hepatobiliary Surg Nutr. 2019 Oct.

. 2019 Oct;8(5):522-524.

doi: 10.21037/hbsn.2019.05.08.

Dong Yun Kim^{1

2}, Jun Yong Park^{2

3

4}

¹ Department of Pharmacology, Yonsei University Graduate School of Medicine, Seoul, South Korea.
² Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
³ Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea.
⁴ Yonsei Liver Center, Severance Hospital, Seoul, South Korea.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Mechanisms of NAFLD development and therapeutic strategies.
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Friedman SL, et al. Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2. Nat Med. 2018. PMID: 29967350 Free PMC article. Review.

1. Hagström H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265-73. 10.1016/j.jhep.2017.07.027 - DOI - PubMed
1. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015;13:643-54.e1-9; quiz e39-40. - PMC - PubMed
1. Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. 10.1002/hep.27368 - DOI - PubMed
1. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-97.e10. 10.1053/j.gastro.2015.04.043 - DOI - PMC - PubMed
1. Myers RP, Elkashab M, Ma M, et al. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol 2010;24:661-70. 10.1155/2010/153986 - DOI - PMC - PubMed